The 22q11.2 region regulates presynaptic gene-products linked to schizophrenia

Ralda Nehme(Broad Institute), Olli Pietiläinen(Broad Institute), Mykyta Artomov(Broad Institute), Matthew Tegtmeyer(Broad Institute), Vera Valakh(Broad Institute), Leevi Lehtonen(University of Helsinki), Christina Bell(Harvard University), Tarjinder Singh(Broad Institute), Aditi Trehan(Broad Institute), J. L. Sherwood(Broad Institute), Danielle K. Manning(Broad Institute), Emily Peirent(Broad Institute), Rhea Malik(Harvard University), Ellen J. Guss(Harvard University), Derek Hawes(Broad Institute), Amanda Beccard(Broad Institute), Anne M. Bara(Broad Institute), Dane Z. Hazelbaker(Broad Institute), Emanuela Zuccaro(Harvard University), Giulio Genovese(Broad Institute), Alexander A. Loboda(Broad Institute), Anna Neumann(Broad Institute), Christina Lilliehöök(Broad Institute), Outi Kuismin(Oulu University Hospital), Eija Hämäläinen(University of Helsinki), Mitja Kurki(Broad Institute), Christina M. Hultman(Karolinska Institutet), Anna K. Kähler(Karolinska Institutet), João A. Paulo(Harvard University), Andrea Ganna(Broad Institute), Jon M. Madison(Broad Institute), Bruce M. Cohen(McLean Hospital), Donna L. McPhie(McLean Hospital), Rolf Adolfsson(Umeå University), Roy H. Perlis(Massachusetts General Hospital), Ricardo E. Dolmetsch(Novartis (United States)), Samouil L. Farhi(Broad Institute), Steven A. McCarroll(Broad Institute), Steven E. Hyman(Broad Institute), Ben Neale(Broad Institute), Lindy E. Barrett(Broad Institute), J. Wade Harper(Harvard University), Aarno Palotie(Broad Institute), Mark J. Daly(Broad Institute), Kevin Eggan(Broad Institute)
Nature Communications
June 27, 2022
Cited by 60Open Access
Full Text

Abstract

It is unclear how the 22q11.2 deletion predisposes to psychiatric disease. To study this, we generated induced pluripotent stem cells from deletion carriers and controls and utilized CRISPR/Cas9 to introduce the heterozygous deletion into a control cell line. Here, we show that upon differentiation into neural progenitor cells, the deletion acted in trans to alter the abundance of transcripts associated with risk for neurodevelopmental disorders including autism. In excitatory neurons, altered transcripts encoded presynaptic factors and were associated with genetic risk for schizophrenia, including common and rare variants. To understand how the deletion contributed to these changes, we defined the minimal protein-protein interaction network that best explains gene expression alterations. We found that many genes in 22q11.2 interact in presynaptic, proteasome, and JUN/FOS transcriptional pathways. Our findings suggest that the 22q11.2 deletion impacts genes that may converge with psychiatric risk loci to influence disease manifestation in each deletion carrier.


Related Papers